PL2861602T3 - 7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on - Google Patents

7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on

Info

Publication number
PL2861602T3
PL2861602T3 PL13725438T PL13725438T PL2861602T3 PL 2861602 T3 PL2861602 T3 PL 2861602T3 PL 13725438 T PL13725438 T PL 13725438T PL 13725438 T PL13725438 T PL 13725438T PL 2861602 T3 PL2861602 T3 PL 2861602T3
Authority
PL
Poland
Prior art keywords
methyl
diazaspiro
nonan
pyrimidin
trifluoromethyl
Prior art date
Application number
PL13725438T
Other languages
English (en)
Polish (pl)
Inventor
Gerard M P Giblin
David T Macpherson
David R Witty
Steven J Stanway
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of PL2861602T3 publication Critical patent/PL2861602T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13725438T 2012-05-22 2013-05-22 7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on PL2861602T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
EP13725438.9A EP2861602B1 (en) 2012-05-22 2013-05-22 7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one

Publications (1)

Publication Number Publication Date
PL2861602T3 true PL2861602T3 (pl) 2017-05-31

Family

ID=46546493

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13725438T PL2861602T3 (pl) 2012-05-22 2013-05-22 7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on
PL16177700T PL3106464T3 (pl) 2012-05-22 2013-05-22 Nowatorskie związki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16177700T PL3106464T3 (pl) 2012-05-22 2013-05-22 Nowatorskie związki

Country Status (27)

Country Link
US (7) US9376445B2 (cg-RX-API-DMAC7.html)
EP (3) EP3106464B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015517562A (cg-RX-API-DMAC7.html)
KR (2) KR20200113027A (cg-RX-API-DMAC7.html)
CN (2) CN107344942B (cg-RX-API-DMAC7.html)
AU (3) AU2013265001B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029280B1 (cg-RX-API-DMAC7.html)
CA (1) CA2873956C (cg-RX-API-DMAC7.html)
CY (2) CY1118274T1 (cg-RX-API-DMAC7.html)
DK (2) DK3106464T3 (cg-RX-API-DMAC7.html)
EA (1) EA025579B1 (cg-RX-API-DMAC7.html)
ES (3) ES2602193T3 (cg-RX-API-DMAC7.html)
GB (1) GB201209015D0 (cg-RX-API-DMAC7.html)
HR (2) HRP20161349T1 (cg-RX-API-DMAC7.html)
HU (2) HUE049445T2 (cg-RX-API-DMAC7.html)
IL (4) IL235805A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02393A (cg-RX-API-DMAC7.html)
LT (2) LT2861602T (cg-RX-API-DMAC7.html)
MX (1) MX355303B (cg-RX-API-DMAC7.html)
PL (2) PL2861602T3 (cg-RX-API-DMAC7.html)
PT (2) PT2861602T (cg-RX-API-DMAC7.html)
RS (2) RS55415B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201703527WA (cg-RX-API-DMAC7.html)
SI (2) SI3106464T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202000210T1 (cg-RX-API-DMAC7.html)
WO (2) WO2013175206A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408253B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
AU2018338884A1 (en) * 2017-09-28 2020-04-16 Biogen Inc. Novel salts
JP2020536898A (ja) * 2017-10-10 2020-12-17 バイオジェン インコーポレイテッド スピロ誘導体を調製するためのプロセス
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451373T1 (de) * 2002-07-05 2009-12-15 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
EP1943216B1 (en) 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
ES2383090T3 (es) * 2005-10-12 2012-06-18 Vertex Pharmaceuticals, Inc. Derivados de bifenilo como moduladores de los canales iónicos dependientes de voltaje
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP2076514A1 (en) 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
JP2010522690A (ja) 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2477964B1 (en) 2009-09-14 2015-02-11 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
EP2829018A1 (en) * 2012-03-21 2015-01-28 Interdigital Patent Holdings, Inc. Sponsoring of a mobile station session by another mobile station in a wireless network
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
ZA201408253B (en) 2015-12-23
IL235805A0 (en) 2015-02-01
AU2017201421B2 (en) 2017-12-07
IL252033B (en) 2019-12-31
IL235805A (en) 2017-05-29
AU2013265001A1 (en) 2014-12-18
CA2873956C (en) 2021-03-23
WO2013175205A1 (en) 2013-11-28
CN107344942B (zh) 2020-09-25
RS55415B1 (sr) 2017-04-28
SI3106464T1 (sl) 2020-12-31
JP2015517561A (ja) 2015-06-22
BR112014029280A2 (pt) 2017-06-27
CA2873956A1 (en) 2013-11-28
JP6378404B2 (ja) 2018-08-22
US9309254B2 (en) 2016-04-12
US9376445B2 (en) 2016-06-28
SG10201703527WA (en) 2017-06-29
PT3106464T (pt) 2020-04-03
AU2018201653A1 (en) 2018-03-29
HK1209423A1 (en) 2016-04-01
CN104640867A (zh) 2015-05-20
GB201209015D0 (en) 2012-07-04
LT2861602T (lt) 2016-11-10
HRP20200580T1 (hr) 2020-10-02
US20200289508A1 (en) 2020-09-17
EP3106464B1 (en) 2020-01-08
US20180360833A1 (en) 2018-12-20
EP2861602A1 (en) 2015-04-22
IN2014MN02393A (cg-RX-API-DMAC7.html) 2015-08-21
US20150166551A1 (en) 2015-06-18
AU2013265001B2 (en) 2016-12-01
US20160263115A1 (en) 2016-09-15
DK3106464T3 (da) 2020-03-23
HUE049445T2 (hu) 2020-09-28
EP2861602B1 (en) 2016-08-10
US10485801B2 (en) 2019-11-26
AU2017201421A1 (en) 2017-03-23
CN104640867B (zh) 2017-07-21
WO2013175206A1 (en) 2013-11-28
JP6169687B2 (ja) 2017-07-26
MX355303B (es) 2018-04-12
AU2018201653B2 (en) 2019-05-02
BR112014029280B1 (pt) 2022-10-04
IL271330A (en) 2020-01-30
EP3106464A1 (en) 2016-12-21
US10010551B2 (en) 2018-07-03
SG11201407755UA (en) 2014-12-30
KR20200113027A (ko) 2020-10-05
IL271330B (en) 2021-02-28
DK2861602T3 (en) 2016-11-28
ES2782088T3 (es) 2020-09-10
IL252033A0 (en) 2017-06-29
PL3106464T3 (pl) 2020-11-16
HRP20161349T1 (hr) 2017-01-27
US20150119404A1 (en) 2015-04-30
EP2861594B1 (en) 2016-08-24
ES2602308T3 (es) 2017-02-20
US20170304303A1 (en) 2017-10-26
CY1118274T1 (el) 2017-06-28
SMT202000210T1 (it) 2020-05-08
US20160184306A1 (en) 2016-06-30
HUE031664T2 (en) 2017-07-28
MX2014014274A (es) 2015-06-17
RS60368B1 (sr) 2020-07-31
KR102161101B1 (ko) 2020-10-20
KR20150023401A (ko) 2015-03-05
IL280595A (en) 2021-03-25
SI2861602T1 (sl) 2017-03-31
LT3106464T (lt) 2020-04-10
EP2861594A1 (en) 2015-04-22
EA025579B1 (ru) 2017-01-30
ES2602193T3 (es) 2017-02-20
JP2015517562A (ja) 2015-06-22
JP2017206534A (ja) 2017-11-24
CN107344942A (zh) 2017-11-14
CY1123044T1 (el) 2021-10-29
SMT201600421B (it) 2017-01-10
US9737536B2 (en) 2017-08-22
PT2861602T (pt) 2016-11-14
EA201492169A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
IL236898A0 (en) 2, 3- benzodiazepines
AP2012006242A0 (en) Anticoagulant antidotes.
PT2861602T (pt) 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-ona
黄蔚阁 et al. 黑龙江八里房矿区地电化学法寻找隐伏金矿床的研究
傅良刚 et al. 粤西罗定盆地周边成矿地质环境与找矿研究
王荣超 et al. 大尹格庄金矿地电提取寻找深部隐伏矿体的试验研究
Grewal When Nice Guys Finish First
李军峰 et al. 山东玲陇金矿低品位矿石的开发利用
田宏伟 et al. 祁雨沟隐爆角砾岩型金矿床资源评价
López-Ruiz Phoenicians
Rodriguez Your eyes, your self
姜维明 et al. 破头青断裂对玲珑金矿田矿体的控制作用浅析
রেজাউল করিম তালুকদার (তারেক রেজা) রবীন্দ্রনাথের গীত-বাণী: বেলা-অবেলার অভয় মন্ত্র
刘文化 et al. 山东官里庄金矿成矿力致热分形弥散分异—富集机理
ARE February
Agerstam The Courtyard
辛志刚 河南下 (坪金矿床成矿地质特征
Bargiel Intermezzo für Orchester, op. 46. Partitur.
陈剑锋 缅甸胶帕图金矿选冶工艺浅议
Cruz et al. En prensa."
Marco Aguilar Six Houses, Paired 2-2
朱松亚 Photo
许洪元 吉林石井金银矿床地质特征及成因探讨
邢洪波 et al. 吉林省南岔含砷金精矿细菌氧化—氰化提金试验研究
徐东 et al. 中深孔采矿法在新城金矿的研究与应用